Monogram Technologies INC 8-K filings

Zimmer Biomet Holdings, Inc. has completed its acquisition of Monogram Technologies Inc., integrating Monogram's AI-driven orthopedic robotics into its portfolio.

Monogram Technologies Inc. stockholders approved the merger with Zimmer Biomet Holdings, Inc., moving closer to a second-half 2025 closing.

Monogram Technologies and Zimmer Biomet extended their merger regulatory review by withdrawing and refiling HSR notifications, pushing the waiting period to October 6, 2025.

Monogram Technologies Inc. is urging stockholders to vote on the proposed acquisition by Zimmer Biomet Holdings, Inc. at a special meeting scheduled for September 30, 2025.

Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. amended their merger agreement to revise the definition of 'Permitted Transfer' in the CVR Agreement following an SEC comment.

Monogram Technologies Inc. has informed its stockholders via text message about the availability of frequently asked questions regarding its proposed acquisition by Zimmer Biomet Holdings, Inc.

Monogram Technologies Inc. has issued an email to stockholders directing them to a new FAQ section on its Investor Relations page to provide clarity on the proposed acquisition by Zimmer Biomet Holdings, Inc.

Monogram Technologies Inc. announced the successful completion of the world's first fully autonomous saw-based robotic knee replacement surgery on a live patient in India, alongside a definitive agreement for its acquisition by Zimmer Biomet Holdings, Inc.

Monogram Technologies Inc. has issued a comprehensive FAQ to its stockholders, clarifying the terms of its proposed acquisition by Zimmer Biomet Holdings, Inc., including the cash consideration and contingent value rights.

Monogram Technologies Inc. has terminated its exclusive license agreement with Icahn School of Medicine at Mount Sinai, settling the obligation with a $4 million payment comprising cash and newly issued Series E Preferred Stock.

Zimmer Biomet Holdings, Inc. has entered into a definitive agreement to acquire Monogram Technologies Inc. for an upfront cash payment of $4.04 per share plus contingent value rights, aiming to enhance its orthopedic robotics portfolio with semiand fully autonomous surgical technologies.

Monogram Technologies Inc. announced the mandatory conversion of all outstanding 8.00% Series D Convertible Cumulative Preferred Stock into common stock, effective July 14, 2025, after its common stock traded at or above $2.8125 for ten consecutive days.

Monogram Technologies has secured regulatory approval from India's Central Drugs Standard Control Organization to conduct clinical trials for its mBs TKA system, marking a significant step towards global expansion.

Monogram Technologies Inc. has received FDA 510(k) clearance for its Monogram mBs TKA System, marking a significant milestone towards commercialization of its robotic-assisted orthopedic surgery technology.

Monogram Technologies announces its full year 2024 financial results, highlights progress on FDA clearance for its mBs TKA System, and reports a strengthened balance sheet.

Monogram Technologies announces its full year 2024 financial results, highlights progress on FDA submission, and discusses strategic collaborations.

Monogram Technologies announces completion of supplemental testing and submission of formal response to the FDA for its mBs TKA System, while also progressing with clinical trial preparations in India.

Monogram Technologies Inc. successfully held its Annual Meeting of Stockholders, electing Class I directors, ratifying the appointment of its accounting firm, and approving amendments to its stock option plan.

Monogram Technologies reports a positive meeting with the FDA regarding its mBs TKA System, anticipating a comprehensive response to the FDA's Additional Information Request in Q1 2025 and potentially avoiding the need for clinical data.

Monogram Technologies announced that related parties, including the CFO, purchased $1 million of the company's common stock, demonstrating confidence in the company's strategy.

Monogram Technologies reported its Q3 2024 financial results, highlighted by a $13 million public offering and progress on FDA clearance for its mBs TKA System.

Monogram Technologies has been recognized as the Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook, highlighting their innovative mBs TKA system.

Monogram Technologies issued a correction to a previous press release, clarifying that the company has 180 days from the receipt of an Additional Information Request (AIR) from the FDA to produce additional information.

Monogram Technologies successfully closed a $13 million Series D preferred stock offering and received an Additional Information Request from the FDA regarding its mBs TKA System.

Monogram Technologies has announced a dividend of $0.0255 per share for its Series D Preferred Stock, payable in kind based on the company's common stock price.

Monogram Technologies has increased its continuous offering of units, each consisting of preferred stock and a warrant, from $10 million to $12.5 million.

Monogram Technologies Inc. has announced its plan to close its Series D Preferred Stock continuous offering on September 12, 2024.

Monogram Technologies has partnered with Shalby Limited for a multicenter clinical trial of its mBs TKA System, marking a significant step towards international expansion.

Monogram Technologies has submitted a 510(k) premarket filing to the FDA for its mBs TKA System, marking a significant step towards commercialization.

Monogram Technologies Inc. has entered into an agreement with B. Riley Securities to sell shares of its common stock through an at-the-market equity offering program.